Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 11/2011

01.11.2011 | Original Article

Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection

verfasst von: Chiara Gaeta, Yolanda Fernández, Javier Pavía, Albert Flotats, Carles Artigas, Jordi Deportos, Llanos Geraldo, Ignasi Carrió

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Physiological glucose uptake by the myocardium may hamper visualization of coronary atherosclerotic plaques in 18F-FDG PET studies. Intracellular myocardial calcium relates to glucose influx. We assessed whether administration of a calcium channel blocker such as verapamil could decrease myocardial 18F-FDG uptake in mice.

Methods

Experiments were conducted on ten male C57BL/6JOlaHsd mice. The mice were studied by 18F-FDG PET/CT under basal conditions and after a single administration of verapamil injected 1 h prior to 18F-FDG administration at doses of 1 mg/kg (group A, n = 5) and 20 mg/kg (group B, n = 5). PET scanning was started 60 min after injection of 18F-FDG employing a dedicated small-animal PET/CT system (ARGUS-CT). In each mouse, post-verapamil PET images were coregistered with the basal PET images. Volumetric regions of interest (VOI) were drawn on the basal study containing the myocardium of the whole left ventricle and quantitatively compared with the same VOI applied to the post-verapamil scan. The SUVmean was used to express the mean myocardial 18F-FDG uptake. The relative coefficient of variation (RV) between the basal and post-verapamil conditions was calculated.

Results

Verapamil administration decreased myocardial 18F-FDG uptake in all animals. The median (range) SUVmean values in group A were 2.6 (1.6–4.1) under basal conditions and 1.7 (1.1–2.9) after verapamil administration (p = 0.043), and in group B were 1.6 (1.3–2.0) under basal conditions and 1.0 (0.9–1.4) after verapamil administration (p = 0.043). The median (range) RV values were −31% (−5%, −50%) in group A, and −37% (−10%, −51%) in group B (p = 0.6).

Conclusion

In this animal model there was a significant reduction in 18F-FDG uptake in the myocardium following verapamil administration. This type of intervention could facilitate the definition of coronary atherosclerotic plaque inflammation on 18F-FDG PET scans.
Literatur
1.
Zurück zum Zitat Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.PubMedCrossRef Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.PubMedCrossRef
2.
Zurück zum Zitat Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.PubMedCrossRef Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.PubMedCrossRef
3.
Zurück zum Zitat Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527–35.PubMedCrossRef Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527–35.PubMedCrossRef
4.
Zurück zum Zitat Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–92.PubMedCrossRef Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–92.PubMedCrossRef
5.
Zurück zum Zitat Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578–88.PubMed Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578–88.PubMed
6.
Zurück zum Zitat Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 853–60. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 853–60.
7.
Zurück zum Zitat Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999–1006.PubMed Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999–1006.PubMed
8.
Zurück zum Zitat Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med. 2011;52(5):800–7.PubMedCrossRef Wong KP, Sha W, Zhang X, Huang SC. Effects of administration route, dietary condition, and blood glucose level on kinetics and uptake of 18F-FDG in mice. J Nucl Med. 2011;52(5):800–7.PubMedCrossRef
9.
Zurück zum Zitat Wang Y, Seidel J, Tsui BM, Vaquero JJ, Pomper MG. Performance evaluation of GE Healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med. 2006;47:1891–900.PubMed Wang Y, Seidel J, Tsui BM, Vaquero JJ, Pomper MG. Performance evaluation of GE Healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med. 2006;47:1891–900.PubMed
10.
Zurück zum Zitat Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25:663–7.PubMed Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25:663–7.PubMed
11.
Zurück zum Zitat Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000;12:191–200.PubMed Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000;12:191–200.PubMed
12.
Zurück zum Zitat Björnheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999;19:870–6.PubMedCrossRef Björnheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999;19:870–6.PubMedCrossRef
13.
Zurück zum Zitat Mayr M, Sidibe A, Zampetaki A. The paradox of hypoxic and oxidative stress in atherosclerosis. J Am Coll Cardiol. 2008;51:1266–7.PubMedCrossRef Mayr M, Sidibe A, Zampetaki A. The paradox of hypoxic and oxidative stress in atherosclerosis. J Am Coll Cardiol. 2008;51:1266–7.PubMedCrossRef
14.
Zurück zum Zitat Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006;188:323–30.PubMedCrossRef Leppänen O, Björnheden T, Evaldsson M, Borén J, Wiklund O, Levin M. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis. 2006;188:323–30.PubMedCrossRef
15.
Zurück zum Zitat Strauss HW, Dunphy M, Tokita N. Imaging the vulnerable plaque: a scintillating light at the end of the tunnel? J Nucl Med. 2004;45:1106–7.PubMed Strauss HW, Dunphy M, Tokita N. Imaging the vulnerable plaque: a scintillating light at the end of the tunnel? J Nucl Med. 2004;45:1106–7.PubMed
16.
Zurück zum Zitat Israel O, Weiler-Sagie M, Rispler S, Bar-Shalom R, Frenkel A, Keidar Z, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med. 2007;48:234–9.PubMed Israel O, Weiler-Sagie M, Rispler S, Bar-Shalom R, Frenkel A, Keidar Z, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med. 2007;48:234–9.PubMed
17.
Zurück zum Zitat Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278–84.PubMed Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278–84.PubMed
18.
Zurück zum Zitat Fine EJ, Miao W, Koba W, Volek JS, Blaufox MD. Chronic effects of dietary carbohydrate variation on [18F]-2-fluoro-2-deoxyglucose uptake in rodent heart. Nucl Med Commun. 2009;30:675–80.PubMedCrossRef Fine EJ, Miao W, Koba W, Volek JS, Blaufox MD. Chronic effects of dietary carbohydrate variation on [18F]-2-fluoro-2-deoxyglucose uptake in rodent heart. Nucl Med Commun. 2009;30:675–80.PubMedCrossRef
19.
Zurück zum Zitat Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–6.PubMedCrossRef Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–6.PubMedCrossRef
20.
Zurück zum Zitat Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol. 2010;17(2):286–91.PubMedCrossRef Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: a randomized controlled trial. J Nucl Cardiol. 2010;17(2):286–91.PubMedCrossRef
21.
Zurück zum Zitat Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.PubMedCrossRef Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.PubMedCrossRef
22.
Zurück zum Zitat Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedCrossRef Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–9.PubMedCrossRef
23.
Zurück zum Zitat Depre C, Ponchaut S, Deprez J, Maisin L, Hue L. Cyclic AMP suppresses the inhibition of glycolysis by alternative oxidizable substrates in the heart. J Clin Invest. 1998;101:390–7.PubMedCrossRef Depre C, Ponchaut S, Deprez J, Maisin L, Hue L. Cyclic AMP suppresses the inhibition of glycolysis by alternative oxidizable substrates in the heart. J Clin Invest. 1998;101:390–7.PubMedCrossRef
24.
Zurück zum Zitat Dobson Jr JG, Ross Jr J, Mayer SE. The role of cyclic adenosine 3′,5′-monophosphate and calcium in the regulation of contractility and glycogen phosphorylase activity in guinea pig papillary muscle. Circ Res. 1976;39:388–95.PubMed Dobson Jr JG, Ross Jr J, Mayer SE. The role of cyclic adenosine 3′,5′-monophosphate and calcium in the regulation of contractility and glycogen phosphorylase activity in guinea pig papillary muscle. Circ Res. 1976;39:388–95.PubMed
Metadaten
Titel
Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection
verfasst von
Chiara Gaeta
Yolanda Fernández
Javier Pavía
Albert Flotats
Carles Artigas
Jordi Deportos
Llanos Geraldo
Ignasi Carrió
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1873-2

Weitere Artikel der Ausgabe 11/2011

European Journal of Nuclear Medicine and Molecular Imaging 11/2011 Zur Ausgabe